2-甲基噻吩并[3,2-d]嘧啶-4(3H)-酮 | 18678-13-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 2-甲基噻吩并[3,2-d]嘧啶-4(3H)-酮
• 中文别名: 2-甲基噻吩并[3,2-D]嘧啶-4(3H)-酮
• 英文名称: 2-methylthieno[3,2-d]pyrimidin-4(3H)-one
• 英文别名: 2-methyl-3H-thieno[3,2-d]pyrimidin-4-one
• CAS: 18678-13-2
• 化学式: C₇H₆N₂OS
• 分子量: 166.203
• InChiKey: IAAFTUOIPKKJAA-UHFFFAOYSA-N

物化性质

• 密度：
  1.53

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2934999090
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P280,P305+P351+P338
• 储存条件：
  室温

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-Methylthieno[3,2-D]Pyrimidin-4(3H)-One
: CBR01498
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 166,2 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-Methylthieno[3,2-D]Pyrimidin-4(3H)-One
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-Methylthieno[3,2-D]Pyrimidin-4(3H)-One
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基噻吩并[3,2-d]嘧啶-4(3H)-酮 在 三氯氧磷 作用下， 反应 5.0h， 以72%的产率得到4-氯-7-甲基噻吩并[3,2-D]嘧啶
  参考文献：
  名称：

  [EN] MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
  [FR] NOUVEAUX COMPOSÉS

  摘要：

  公开号：

  WO2012156756A3
• 作为产物：
  描述：

  3-(乙酰基氨基)-2-噻吩羧酸甲酯 在 ammonium hydroxide 作用下， 反应 3.0h， 以63%的产率得到2-甲基噻吩并[3,2-d]嘧啶-4(3H)-酮
  参考文献：
  名称：

  通过对4-取代的2-三氯甲基喹唑啉抗血浆支架的全球SAR研究发现了针对恶性疟原虫的新型命中分子

  摘要：

  我们从2-三氯甲基喹唑啉系列中鉴定出的4种抗血浆击中分子中，进行了涉及26种化合物并涵盖5个分子区域（IV）的全局结构-活性关系（SAR）研究，旨在定义相应的药效团并鉴定新的生物活性衍生物。 。因此，在详细研究了苯胺部分后，合成了噻吩并嘧啶，喹啉和喹喔啉生物异构体，并在K1多耐药性恶性疟原虫上进行了测试。菌株，以及对人类HepG2细胞系的细胞毒性评估，以定义选择性指标。SAR首先显示，噻吩并嘧啶和喹啉在全球范围内具有更高的细胞毒性，而喹喔啉类似物的活性和毒性都比喹唑啉类似物低。在喹喔啉一系列这样pharmacomodulation不仅提供了新的抗疟原虫参考命中分子（IC 50  = 0.4μM，选择性指数= 100），但也突出的活性（IC 50  = 0.4μM）和相当选择性的（SI = 265）的合成中间。

  DOI：

  10.1016/j.ejmech.2016.09.029
• 作为试剂：
  描述：

  3-acetamidothiophene-2-carboxamide 、 sodium hydroxide 、 盐酸 在 水 、 2-甲基噻吩并[3,2-d]嘧啶-4(3H)-酮 作用下， 以 水 为溶剂， 反应 2.0h， 以to afford 2-methylthieno[3,2-d]pyrimidin-4-ol (Compound 139; 12.5 g, 91%), which的产率得到2-甲基噻吩并[3,2-d]嘧啶-4(3H)-酮
  参考文献：
  名称：

  THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS

  摘要：

  本文提供了一种新型的取代噻吩[3,2-d]嘧啶-6-羧酰胺sirtuin抑制剂及其使用方法。这些sirtuin抑制剂可用于抑制sirtuin介导的生物过程，例如用于治疗和/或预防癌症、神经退行性疾病和炎症等疾病和疾患。本文还提供了包含这些sirtuin抑制剂的制药组合物和包含sirtuin抑制剂与另一种治疗剂的组合物。

  公开号：

  US20160002273A1

文献信息

• Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors
  作者：Colin R. O’Dowd、Matthew D. Helm、J. S. Shane Rountree、Jakub T. Flasz、Elias Arkoudis、Hugues Miel、Peter R. Hewitt、Linda Jordan、Oliver Barker、Caroline Hughes、Ewelina Rozycka、Eamon Cassidy、Keeva McClelland、Ewa Odrzywol、Natalie Page、Stephanie Feutren-Burton、Scarlett Dvorkin、Gerald Gavory、Timothy Harrison

  DOI：10.1021/acsmedchemlett.7b00512

  日期：2018.3.8

  potential involvement in oncogenic pathways as well as possible roles in both metabolic and immune disorders in addition to viral infections. Potent, novel, and selective inhibitors of USP7 have been developed using both rational and structure-guided design enabled by high-resolution cocrystallography. Initial hits were identified via fragment-based screening, scaffold-hopping, and hybridization exercises

  泛素特异性蛋白酶7（USP7，HAUSP）由于在调节Mdm2水平（进而调节p53）中的作用，已成为药物发现中的引人注目的靶标。由于USP7可能参与致癌途径以及除病毒感染外在代谢和免疫疾病中的可能作用，因此人们对USP7的兴趣也越来越高。USP7的强效，新型和选择性抑制剂已通过高分辨率共结晶技术的合理设计和结构指导设计得到开发。最初的命中是通过基于片段的筛选，支架跳跃和杂交练习来确定的。描述了两个不同的子系列以及相关的结构-活性关系趋势，以及旨在开发适用于体内化合物的初步努力实验。总体而言，这些发现将有助于进一步研究USP7的更广泛的生物学作用。
• Chemical Space Exploration around Thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one Scaffold Led to a Novel Class of Highly Active <i>Clostridium difficile</i> Inhibitors
  作者：Xuwei Shao、Ahmed AbdelKhalek、Nader S. Abutaleb、Uday Kiran Velagapudi、Sabesan Yoganathan、Mohamed N. Seleem、Tanaji T. Talele

  DOI：10.1021/acs.jmedchem.9b01198

  日期：2019.11.14

  treatments for CDI is a high priority. Toward this goal, we began in vitro screening of a structurally diverse in-house library of 67 compounds against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compound, 2-methyl-8-nitroquinazolin-4(3H)-one (2) with moderate potency (MIC = 312/156 μM). Optimization of 2 gave lead compound 6a (2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one)

  艰难梭菌感染（CDI）是美国医疗保健相关感染的主要原因。因此，开发用于CDI的新疗法是当务之急。为了实现这一目标，我们开始体外筛选针对两种致病性艰难梭菌菌株（ATCC BAA 1870和ATCC 43255）的67种化合物的结构多样的内部文库，产生的化合物为2-甲基-8-硝基喹唑啉酮- 4（3 H）-一（2），具有中等效力（MIC = 312/156μM）。2的最优化得到铅化合物6a（2-甲基-7-硝基硫代[3,2 - d ]嘧啶-4（3 H-1）具有增强的效价（MIC = 19/38μM），对正常肠道菌群的选择性，对哺乳动物细胞系的CC 50 s> 606μM ，以及在模拟的胃液和肠液中的可接受的稳定性。在C2-，N3-，C4-和C7位置上对6a的进一步优化导致了针对50多种化合物的文库，其针对艰难梭菌的临床分离株的MIC为3至800μM。化合物8f（MIC = 3/6μM）被确定为进一步优化的有希望的先导。
• Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold
  作者：Ana I. Sánchez、Ricardo Meneses、José M. Mínguez、Araceli Núñez、Rafael R. Castillo、Fabiana Filace、Carolina Burgos、Juan J. Vaquero、Julio Álvarez-Builla、Alvaro Cortés-Cabrera、Federico Gago、Emma Terricabras、Víctor Segarra

  DOI：10.1039/c4ob00175c

  日期：——

  Thienopyrimidin-4-amines have been synthesized, evaluated and modelled as phosphodiesterase inhibitors.

  噻唑嘧啶-4-胺已被合成、评估并建模为磷酸二酯酶抑制剂。
• SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150329556A1

  公开（公告）日：2015-11-19

  The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR 1 (R 1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R 2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH 2 ), and at least one of ring B and ring C has substituent(s), provided that N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

  本发明提供了一种新型酰胺衍生物，具有基质金属蛋白酶抑制活性，并且作为药用剂是有用的，该化合物由以下式(I)表示，其中环A是一个可选择取代的含氮杂环，环B是一个可选择取代的单环同核环或可选择取代的单环杂环，Z是N或NR1（R1是氢原子或可选择取代的碳氢基团），是一个单键或双键，R2是氢原子或可选择取代的碳氢基团，X是一个具有1到6个原子的可选择取代的间隔物，环C是（1）一个可选择取代的同核环或（2）一个除了由（II）表示的环之外的可选择取代的杂环（X′是S、O、SO或CH2），并且环B和环C中至少有一个有取代基，但不包括N-(1S,2R)-1-(3,5-二氟苄基)-3-[(3-乙基苄基)氨基]2-羟基丙基}5,6-二甲基-4-氧代-1,4-二氢噻唑并[2,3-d]嘧啶-2-羧酰胺，或其盐。
• [EN] SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE<br/>[FR] INHIBITEURS SÉLECTIFS DE MUTANTS CLINIQUEMENT IMPORTANTS DE LA TYROSINE KINASE DE L'EGFR
  申请人：CS PHARMASCIENCES INC

  公开号：WO2017120429A1

  公开（公告）日：2017-07-13

  The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

  本发明提供了式（I）的化合物或其亚类结构或种属，或其药学上可接受的盐、酯、溶剂化合物和/或前药，以及用于治疗或改善异常细胞增殖性疾病，如癌症的方法和组合物，其中A、R2、R3、R10、E1、E2、E3、Y和Z如本文所定义。